Skip to main content

Cardiovascular

Featured Article
In a recent study, researchers compared effectiveness and safety of antihypertensive drugs and outcomes from observational data from 4.9 million patients.
“This study reveals that [people living with HIV] may be at a substantial disadvantage in terms of receiving correct statin therapy for ASCVD risk reduction,” the researchers concluded.

Insights

Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
Mahmoud Barbarawi, MD, department of internal medicine at the Hurley Medical Center (Flint, Michigan), shares insights from his recent study and highlights gaps of knowledge that still exist between vitamin D supplementation and cardiovascular…
Kiersten Combs, vice president of US Cardiovascular & Metabolic Disease, and Jim McDermott, vice president of US Medical Affairs and Metabolism, both at AstraZeneca, highlight how the use of Farxiga and other SGLT2 inhibitors impact payers and…
Mark Munger, PharmD, explains why there is a critical need to develop a treatment to reduce the incidence of NSAID-induced cardiovascular adverse events, especially heart failure.
Back to Top